Patient demographics and baseline disease characteristics. Data are mean ± SD unless indicated otherwise.
| Characteristics | ADA + 7.5 mg | ADA + 20 mg | |
|---|---|---|---|
| MTX, n = 154 | MTX, n = 155 | Total, n = 309 | |
| Age, yrs | 55.1 ± 13.1 | 54.5 ± 11.1 | 54.8 ± 12.1 |
| Age ≥ 65, n (%) | 37 (24.0) | 32 (20.6) | 69 (22.3) |
| Female, n (%) | 120 (77.9) | 111 (71.6) | 231 (74.8) |
| Hispanic or Latino, n (%) | 34 (22.1) | 39 (25.2) | 73 (23.6) |
| RA duration, yrs | 5.9 ± 8.5 | 4.7 ± 6.5 | 5.3 ± 7.6 |
| Prior medication, n (%) | |||
| ≥ 1 NSAID | 92 (59.7) | 87 (56.1) | 179 (57.9) |
| ≥ 1 systemic corticosteroid | 62 (40.3) | 67 (43.2) | 129 (41.7) |
| Mean oral corticosteroid dose, mg/day | 5.4 ± 1.8 | 5.0 ± 1.4 | 5.2 ± 1.6 |
| 1 biologic DMARD | 10 (6.5) | 7 (4.5) | 17 (5.5) |
| Prior MTX use, mg/week, n (%) | |||
| 15 | 76 (49.4) | 75 (48.4) | 151 (48.9) |
| 17.5 | 19 (12.3) | 21 (13.5) | 40 (12.9) |
| ≥ 20 | 59 (38.3) | 59 (38.1) | 118 (38.2) |
| Duration of prior MTX use, mg/week, yrs | |||
| 15 | 1.8 ± 3.3 | 1.3 ± 2.5 | 1.5 ± 2.9 |
| 17.5 | 1.1 ± 1.3 | 1.3 ± 1.3 | 1.2 ± 1.3 |
| ≥ 20 | 1.4 ± 2.0 | 1.7 ± 3.9 | 1.5 ± 3.1 |
| TJC68 | 31.1 ± 16.8 | 31.4 ± 17.3 | 31.2 ± 17.0 |
| SJC66 | 17.8 ± 10.1 | 18.9 ± 11.6 | 18.3 ± 10.9 |
| TJC28 | 16.2 ± 7.1 | 16.1 ± 7.4 | 16.2 ± 7.2 |
| SJC28 | 12.0 ± 5.7 | 12.4 ± 5.8 | 12.2 ± 5.7 |
| PGA disease activity, VAS 0–100 mm | 61.6 ± 20.6 | 61.1 ± 19.7 | 61.3 ± 20.1 |
| PtGA disease activity, VAS 0–100 mm | 62.6 ± 22.3 | 65.0 ± 23.4 | 63.8 ± 22.8 |
| Patient pain, VAS 0–100 mm | 65.3 ± 21.0 | 68.3 ± 20.8 | 66.8 ± 20.9 |
| CRP, mg/l | 15.4 ± 23.6 | 13.8 ± 18.8 | 14.6 ± 21.3 |
| CRP abnormal, ≥ 9 mg/l, n (%) | 64 (41.6) | 67 (43.2) | 131 (42.4) |
| Anti-CCP, units | 1264 ± 2393 | 1129 ± 2170 | 1197 ± 2281 |
| Anti-CCP–positive, ≥ 20 units, n (%) | 106 (70.2) | 111 (73.0) | 217 (71.6) |
| RF, IU/ml | 221.8 ± 385.6 | 175.1 ± 348.5 | 198.4 ± 367.6 |
| RF positive, ≥ 12 IU/ml, n (%) | 106 (69.7) | 104 (68.0) | 210 (68.9) |
| DAS28-CRP | 5.8 ± 0.92 | 5.8 ± 0.96 | 5.8 ± 0.94 |
| SDAI | 42.1 ± 13.7 | 42.6 ± 13.3 | 42.4 ± 13.5 |
| CDAI | 40.6 ± 12.9 | 41.3 ± 12.9 | 40.9 ± 12.9 |
| HAQ-DI | 1.45 ± 0.59 | 1.47 ± 0.65 | 1.46 ± 0.62 |
| Bony erosion (0–22) | 1.6 ± 2.3 | 1.7 ± 2.1 | 1.6 ± 2.2 |
| Synovial hypertrophy (0–48) | 33.4 ± 7.6 | 34.0 ± 7.0 | 33.7 ± 7.3 |
| Synovial vascularity (0–48) | 5.9 ± 5.7 | 5.7 ± 5.1 | 5.8 ± 5.4 |
ADA: adalimumab; MTX: methotrexate; RA: rheumatoid arthritis; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; TJC: tender joint count; SJC: swollen joint count; PGA: physician’s global assessment; VAS: visual analog scale; PtGA: patient’s global assessment; CRP: C-reactive protein; anti-CCP: anticyclic citrullinated protein; RF: rheumatoid factor; DAS28: 28-joint count Disease Activity Score; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index; HAQ-DI: Health Assessment Questionnaire–Disability Index.